|Daily Range||$21.77 - $22.60|
|52-Week Range||$13.02 - $22.95|
|Dividend (Yield)||$0.00 (0.0%)|
|Average Daily Volume||134,316|
|Current FY EPS||$0.80|
Emergent BioSolutions (EBS) Description
Emergent BioSolutions makes the only FDA-approved anthrax vaccine. Website: http://www.emergentbiosolutions.com/
Emergent BioSolutions Presents Positive Interim Phase 2 Data Evaluating Otlertuzumab in Combination with Bendamustine in People with Relapsed Chronic Lymphocytic Leukemia
Gilead Sciences is widely known for its HIV drug portfolio and for its high-profile hep-C drug sofosbuvir. But it also has a potential winner with idelalisib, a blood cancer drug with a promising future.
Biological and chemical agents are a lethal scourge of war, but Emergent Biosciences is developing countermeasures to a wide range of such agents.